Australia's most trusted
source of pharma news
Posted 17 October 2024 AM
A new partnership between Commercial Eyes and AI experts Opyl will offer rich competitive intelligence data including pinpointing the most promising therapies being trialled, likelihood of trial success, timelines to commercialisation and even the chances of an HTA victory.
The service agreement announced yesterday will allow Commercial Eyes to leverage Opyl's AI-driven platform called TrialKey to enhance market research and competitive intelligence for potentially more than 1,000 clients, including 75 per cent of the world's largest pharmaceutical companies.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.